Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseasesLong-term data supporting soticlestat safety, tolerability and seizure-reduction. | May 5, 2023
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating)’s share price was up 0.3% during mid-day trading on Wednesday . The company traded as high as $3.65 and last traded at $3.61. Approximately 129,235 shares traded hands during mid-day trading, an increase of 68% from the average daily volume of 77,129 shares. The stock had previously closed […]
Form S-8 Ovid Therapeutics Inc. streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in. | May 1, 2023